RUTGERS, THE STATE UNIVERSITY

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Inflammation and the Host Response to Injury (In Healthy Volunteers)

Phase 1

Completed

Conditions: Immune System

Interventions: Biological: Endotoxin, Lipopolysaccharide, LPS

First Posted Date: 2009-01-12

Last Posted Date: 2014-05-21

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 116

Registration Number: NCT00820989

Locations: 🇺🇸
Rutgers-RWJMS, New Brunswick, New Jersey, United States

Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers

Withdrawn

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Brain and Central Nervous System Tumors
Depression
Lymphoma
Myelodysplastic Syndromes
Psychosocial Effects of Cancer and Its Treatment
Chronic Myeloproliferative Disorders
Leukemia
Multiple Myeloma and Plasma Cell Neoplasm
Myelodysplastic/Myeloproliferative Neoplasms

First Posted Date: 2008-10-10

Last Posted Date: 2015-05-29

Lead Sponsor: Rutgers, The State University of New Jersey

Registration Number: NCT00770419

Medical Nutrition Therapy or Standard Care in Treating Patients With Lung Cancer, Pancreatic Cancer, or Stage III or Stage IV Prostate Cancer

Not Applicable

Terminated

Conditions: Lung Cancer
Pancreatic Cancer
Malnutrition
Weight Changes
Prostate Cancer

Interventions: Behavioral: Medical nutrition therapy
Behavioral: Standard Care

First Posted Date: 2008-10-09

Last Posted Date: 2023-10-03

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 8

Registration Number: NCT00769652

Locations: 🇺🇸
Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States

The Effects of Epinephrine in Endotoxemia in Normal Volunteers

Phase 1

Completed

Conditions: Immune System

Interventions: Biological: Endotoxin, Lipopolysaccharide, LPS
Biological: Endotoxin, Epinephrine

First Posted Date: 2008-09-16

Last Posted Date: 2015-05-27

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 37

Registration Number: NCT00753402

Locations: 🇺🇸
Rutgers-RWJMS, New Brunswick, New Jersey, United States

Hydroxychloroquine in Treating Patients With Rising PSA Levels After Local Therapy for Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: hydroxychloroquine

First Posted Date: 2008-08-01

Last Posted Date: 2022-06-16

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 64

Registration Number: NCT00726596

Locations: 🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Carol G. Simon Cancer Center at Morristown Memorial Hospital, Morristown, New Jersey, United States
🇺🇸
Cancer Institute of New Jersey at Hamilton, Hamilton, New Jersey, United States

and more 2 locations

Propofol Concentration In The Ambient Air Of The Operating Room And In The Blood Of Anesthesia Care Providers

Completed

Conditions: Propofol Pollution

First Posted Date: 2008-06-12

Last Posted Date: 2013-12-11

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 20

Registration Number: NCT00695799

Locations: 🇺🇸
UMDNJ, Newark, New Jersey, United States

Effects of Nitrous Oxide on Intraocular Pressure

Terminated

Conditions: Post Operative Visual Loss

First Posted Date: 2008-06-12

Last Posted Date: 2015-04-24

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 30

Registration Number: NCT00696189

Locations: 🇺🇸
UMDNJ, Newark, New Jersey, United States

Phase I/II Trial of Letrozole and Sorafenib in Post-Menopausal Hormone-Receptor + Breast Cancer

Phase 1

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Sorafenib
Drug: Letrozole

First Posted Date: 2008-03-13

Last Posted Date: 2023-11-09

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 52

Registration Number: NCT00634634

Locations: 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
🇺🇸
Cooper Hospital/University Medical Center, Voorhees, New Jersey, United States

and more 1 locations

A Phase I/II Trial of 2-Deoxyglucose (2DG) for the Treatment of Advanced Cancer and Hormone Refractory Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer

Interventions: Drug: 2-deoxyglucose

First Posted Date: 2008-03-11

Last Posted Date: 2023-12-22

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 12

Registration Number: NCT00633087

Locations: 🇺🇸
The Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer

Phase 2

Completed

Conditions: Metastatic Breast Cancer

Interventions: Drug: Doxil
Drug: Carboplatin
Drug: Bevacizumab

First Posted Date: 2008-02-06

Last Posted Date: 2023-02-08

Lead Sponsor: Rutgers, The State University of New Jersey

Target Recruit Count: 31

Registration Number: NCT00608972

Locations: 🇺🇸
Saint Peter's University Hospital, New Brunswick, New Jersey, United States
🇺🇸
Jersey Shore University Medical Center, Neptune, New Jersey, United States
🇺🇸
Cooper Hospital/University Medical Center, Camden, New Jersey, United States

and more 4 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy